A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.

Also called NCT01810939

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 243 participants (enrolled count) (from the registry)
Sponsor
  • Relypsa, Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01810939
  • EudraCT 2012-001956-20
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Croatia, Czechia, Denmark, Georgia, Hungary, Italy, Serbia, Slovenia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01810939. Randomized; single masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2015-12-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Acronym
OPAL
Condition
Hyperkalemia (HK)
Intervention (Drug)
Patiromer
Intervention (Drug)
Placebo
Lead sponsor
Relypsa, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01810939
Content hash
2d491d2f1e1e6c2889bd283a66e10f89d4961a17d74a6cc3122b280b8ab0db5a